Regeneron Pharmaceuticals (REGN) R&D In Process (2021 - 2025)
Historic R&D In Process for Regeneron Pharmaceuticals (REGN) over the last 5 years, with Q4 2025 value amounting to $18.7 million.
- Regeneron Pharmaceuticals' R&D In Process rose 3550.72% to $18.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $124.1 million, marking a year-over-year increase of 2287.13%. This contributed to the annual value of $124.1 million for FY2025, which is 2287.13% up from last year.
- According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' R&D In Process is $18.7 million, which was up 3550.72% from $83.1 million recorded in Q3 2025.
- In the past 5 years, Regeneron Pharmaceuticals' R&D In Process ranged from a high of $197.0 million in Q2 2022 and a low of $7.1 million during Q1 2024
- Over the past 5 years, Regeneron Pharmaceuticals' median R&D In Process value was $30.0 million (recorded in 2022), while the average stood at $47.6 million.
- Its R&D In Process has fluctuated over the past 5 years, first skyrocketed by 9964.41% in 2023, then tumbled by 8734.4% in 2024.
- Regeneron Pharmaceuticals' R&D In Process (Quarter) stood at $48.0 million in 2021, then plummeted by 37.5% to $30.0 million in 2022, then changed by 0.0% to $30.0 million in 2023, then plummeted by 54.0% to $13.8 million in 2024, then surged by 35.51% to $18.7 million in 2025.
- Its R&D In Process stands at $18.7 million for Q4 2025, versus $83.1 million for Q3 2025 and $10.0 million for Q2 2025.